These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28056874)

  • 1. Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.
    Zhang HL; Sheng XN; Li XS; Wang HK; Chi ZH; He ZS; Ye DW; Guo J
    BMC Cancer; 2017 Jan; 17(1):16. PubMed ID: 28056874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
    Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.
    Zhang Y; Li Y; Cai Y; Wang K; Li H
    Cell Oncol (Dordr); 2016 Feb; 39(1):15-21. PubMed ID: 26597814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
    Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
    J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
    Poprach A; Pavlik T; Melichar B; Puzanov I; Dusek L; Bortlicek Z; Vyzula R; Abrahamova J; Buchler T;
    Ann Oncol; 2012 Dec; 23(12):3137-3143. PubMed ID: 22700990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
    Derbel Miled O; Dionne C; Terret C; Segura-Ferlay C; Flechon A; Neidhart EM; Negrier S; Droz JP
    J Geriatr Oncol; 2013 Jul; 4(3):255-61. PubMed ID: 24070463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
    Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
    BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
    Bourlon MT; Gao D; Trigero S; Clemons JE; Breaker K; Lam ET; Flaig TW
    Cancer Med; 2016 Dec; 5(12):3386-3393. PubMed ID: 27758076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
    Riesenbeck LM; Bierer S; Hoffmeister I; Köpke T; Papavassilis P; Hertle L; Thielen B; Herrmann E
    World J Urol; 2011 Dec; 29(6):807-13. PubMed ID: 21153827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
    Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
    Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
    Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
    Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
    Haas NB; Manola J; Dutcher JP; Flaherty KT; Uzzo RG; Atkins MB; DiPaola RS; Choueiri TK
    JAMA Oncol; 2017 Sep; 3(9):1249-1252. PubMed ID: 28278333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kusuda Y; Harada K; Sakai I; Fujisawa M
    Int J Clin Oncol; 2013 Feb; 18(1):81-6. PubMed ID: 22095244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
    Iacovelli R; Lanoy E; Albiges L; Escudier B
    BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.